Fig. 6: Drug treatment of xenografted zebrafish larvae.
From: Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
A Zebrafish larvae xenotransplanted with DiI-labeled (red) MCF-7 or HCC1806 human breast cancer cells were treated from 1–3 days post injection (dpi) with 0.20% DMSO, or a combination of 20 nM bortezomib and 25 µM nedaplatin or 20 µM carboplatin and 20 nM paclitaxel. Dot plots show relative change in tumor volume from baseline in MCF-7 treated with 0.20% DMSO (n = 14), 20 nM bortezomib and 25 µM nedaplatin (n = 13) or 20 µM carboplatin and 20 nM paclitaxel (n = 8) plotted as B mean with standard deviation C or individually. Dot plots show the relative change in tumor volume from baseline in HCC1806 treated with 0.20% DMSO (n = 15), 20 nM bortezomib and 25 µM nedaplatin (n = 6) or 20 µM carboplatin and 20 nM paclitaxel (n = 7) plotted as D mean with standard deviation E or as individual larvae. The dotted line indicates relative volume at 1 dpi.
